Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis

Vitamin E improves liver histology in adults with nonalcoholic steatohepatitis (NASH) but not diabetes, but its impact on long‐term patient outcomes is unknown. We evaluated whether vitamin E treatment improves clinical outcomes of NASH patients with bridging fibrosis or cirrhosis. Two hundred and thirty‐six patients with biopsy‐proven NASH and bridging fibrosis or cirrhosis seen at Indiana University Medical Center between October 2004 and January 2016 were included. Ninety of them took 800 international units/day of vitamin E for ≥2 years (vitamin E users) and were propensity‐matched to 90 adults who did not take vitamin E (controls) after adjusting for fibrosis severity, age, gender, body mass index, comorbidities and their treatment, low‐density lipoprotein cholesterol, liver biochemistries, and length of follow‐up on vitamin E. Covariate‐adjusted Cox and competing risk regression models were assessed to evaluate the association between vitamin E treatment and patient outcomes. The median follow‐up was 5.62 (interquartile range [IQR], 4.3‐7.5) and 5.6 (IQR, 4‐6.9) years for vitamin E users and controls, respectively. Vitamin E users had higher adjusted transplant‐free survival (78% versus 49%, P < 0.01) and lower rates of hepatic decompensation (37% versus 62%, P = 0.04) than controls. After controlling for severity of fibrosis, calendar year of patient enrollment, and other potential confounders, vitamin E treatment decreased the risk of death or transplant (adjusted hazard ratio, 0.30; 95% confidence interval [CI], 0.12‐0.74; P < 0.01) and hepatic decompensation (adjusted sub‐HR, 0.52; 95% CI, 0.28‐0.96; P = 0.036). These benefits were evident in both those with diabetes and those without diabetes. Adjusted 10‐year cumulative probabilities of hepatocellular carcinoma, vascular events, and nonhepatic cancers were not different between vitamin E–exposed patients and controls. Conclusion: Vitamin E use was associated with improved clinical outcomes in patients with NASH and bridging fibrosis or cirrhosis.

• Publication year

  2020

• Venue

  Hepatology

• Publication date

  2020-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.30368PMID 30506586
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.

  2018cited by this paper
• A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

  2018cited by this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018influential reference
• Low Vitamin E Levels in NAFLD Patients are Associated with Increased All-Cause Mortality: A 23-Year Prospective Population-Based Study

  2017cited by this paper
• The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

  2017cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

  2016cited by this paper
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

  2016cited by this paper
• Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

  2016cited by this paper
• Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

  2015cited by this paper
• Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

  2015cited by this paper
• Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

  2015cited by this paper
• Methods for constructing and assessing propensity scores.

  2014cited by this paper
• Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases.

  2014cited by this paper
• Isoforms of Vitamin E Differentially Regulate PKC α and Inflammation: A Review.

  2013cited by this paper
• Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.

  2013influential reference
• Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)

  2012cited by this paper
• Features, diagnosis, and treatment of nonalcoholic fatty liver disease.

  2012cited by this paper
• The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

  2012cited by this paper
• Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH)

  2011cited by this paper
• Management of hepatocellular carcinoma: An update

  2011cited by this paper
• Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

  2011influential reference
• Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

  2011cited by this paper
• Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

  2011cited by this paper
• Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT )

  2011cited by this paper
• Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-One Matching on the Propensity Score

  2010cited by this paper
• Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials.

  2010cited by this paper
• Gene-Regulatory Activity of α-Tocopherol

  2010cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010influential reference
• Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials

  2010cited by this paper
• Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease

  2010cited by this paper
• Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis.

  2009cited by this paper
• Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice

  2009cited by this paper
• Management of adult patients with ascites due to cirrhosis: An update

  2009cited by this paper
• Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

  2007cited by this paper
• Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.

  2006influential reference
• Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality

  2005cited by this paper
• Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods.

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

  2003influential reference
• Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.

  2003cited by this paper
• The potential role of antioxidant vitamins in preventing cardiovascular diseases and cancers.

  1998cited by this paper
• Alpha-Tocopherol But Not Beta-Tocopherol Inhibits Thrombin-Induced PKC Activation and Endothelin Secretion in Endothelial Cells

  1998cited by this paper
• Inhibition of cell proliferation by alpha-tocopherol. Role of protein kinase C.

  1991cited by this paper
• American Association for the Study of Liver Diseases

  1959cited by this paper
• Ela fi branor , an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

  year unknowncited by this paper

• Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis

  2026cites this paper
• MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management-A Narrative Review.

  2026cites this paper
• Vitamin E Modulates Hepatic Extracellular Adenosine Signaling to Attenuate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2026cites this paper
• Natural, Engineered, and Hybrid Platelet Membrane–Based Nanotherapeutics for Inflammatory Diseases

  2025cites this paper
• Nutrition and Liver Disease

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease: Role in the development of comorbid conditions and therapeutic management

  2025cites this paper
• Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis

  2025cites this paper
• Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?

  2025cites this paper
• Current Research Status of Pharmacotherapy for Non-Alcoholic Fatty Liver Disease (NAFLD)

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease in metabolic syndrome

  2025cites this paper
• Impact of Saroglitazar on Liver Stiffness Measurements in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With Compensated Cirrhosis: A Single-Arm Study

  2025cites this paper
• Dietary vitamin E intake is associated with lower mortality among individuals with metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD.

  2025cites this paper
• Discovery of a Novel Silybin Derivative for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease in people with HIV

  2025cites this paper
• Reducing complications of metabolic dysfunction–associated steatotic liver disease

  2025cites this paper
• Nutraceutical Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Path to Liver Health

  2025cites this paper
• ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease

  2025cites this paper
• Treatment Resistant Patients with Metabolic Dysfunction-associated Steatohepatitis: Long-term Follow-up Prospective Study

  2025cites this paper
• Current understanding on inferior quality of liver grafts by donation after circulatory death based on multi-omics data

  2025cites this paper
• Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community

  2025cites this paper
• Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes.

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease in adults

  2025cites this paper
• The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

  2025cites this paper
• Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study

  2025cites this paper
• KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

  2025cites this paper
• Development of Subtle Iron Deficiency During Vitamin E Treatment For Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• At the Crossroads of Health and Disease: Consequences of Fat in the Liver

  2025cites this paper
• Abscisic acid improves non-alcoholic fatty liver disease in mice through the AMPK/NRF2/KEAP1 signaling axis.

  2025cites this paper
• Non-Pharmacological and Pharmacological Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): An Update

  2025cites this paper
• Efficacy of pharmacotherapies on pediatric patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis

  2025cites this paper
• Nutrition in MASLD: a patient focused, evidence-based clinician’s guide

  2025cites this paper
• Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography

  2024cites this paper
• Metabolic dysfunction-associated steatotic liver disease throughout the liver transplant cycle: a comprehensive review

  2024cites this paper
• Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)

  2024cites this paper
• Addressing the essentials of the recent guidelines for managing patients with metabolic dysfunction-associated steatotic liver disease

  2024cites this paper
• Antioxidants and the risk of metabolic dysfunction-associated steatotic liver disease: results of National Health and Nutrition Examination Survey and two-sample Mendelian randomization analyses

  2024cites this paper
• VITAMIN E SHIELDS AGAINST ALCOHOLIC TOXICITY BY SAFEGUARDING HEPATIC PARENCHYMAL MORPHOLOGY AND LOWERING BLOOD ALT LEVELS.

  2024cites this paper
• A PRAGMATIC MANAGEMENT APPROACH FOR METABOLIC DYSFUNCTION ASSOCIATED STEATOSIS AND STEATOHEPATITIS.

  2024cites this paper
• Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease.

  2024cites this paper
• Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review

  2024cites this paper
• Practice Recommendations for Metabolic Dysfunction–Associated Steatotic Liver Disease by the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN)

  2024cites this paper
• Oxidative Stress and Annexin A2 Differential Expression in Free Fatty Acids-Induced Non-Alcoholic Fatty Liver Disease in HepG2 Cells

  2024cites this paper
• Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment

  2024cites this paper
• Transcriptomic Landscape Analysis Reveals a Persistent DNA Damage Response in Metabolic Dysfunction-associated Steatohepatitis Post-dietary Intervention

  2024cites this paper
• Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2024influential citation
• RETRACTED ARTICLE: Association between the composite dietary antioxidant index and metabolic dysfunction-associated steatotic liver disease in adults: a cross-sectional study from NHANES 2017–2020

  2024cites this paper
• EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

  2024cites this paper
• EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2024cites this paper
• Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?

  2024cites this paper
• Fluorescence imaging sheds light on the immune evasion mechanisms of hepatic stellate cells mediated by superoxide anion

  2024cites this paper
• New and emerging treatments for metabolic dysfunction-associated steatohepatitis.

  2024cites this paper
• Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology.

  2024cites this paper
• Exploring the interactions between metabolic dysfunction-associated fatty liver disease and micronutrients: from molecular mechanisms to clinical applications

  2024cites this paper
• Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis

  2024cites this paper
• Review and expert opinion on MAFLD, oxidative stress and multifunctional management

  2024cites this paper
• The Link between NAFLD and Metabolic Syndrome

  2023cites this paper
• Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)

  2023cites this paper
• MASLD treatment—a shift in the paradigm is imminent

  2023cites this paper
• Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease.

  2023cites this paper
• Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention

  2023cites this paper
• Extracellular Vesicles and Fatty Liver.

  2023cites this paper
• Diets with Higher Anti-inflammatory Potential Associated with Lower Risk of Development of Nonalcoholic Fatty Liver Disease and Early-Stage of Fibrosis Among US Adults

  2023cites this paper
• In-silico, in-vitro and ex-vivo evidence of combining silymarin phytopharmaceutical with piperine, and fulvic acid for enhancing its solubility and permeability

  2023cites this paper
• Bệnh gan nhiễm mỡ liên quan chuyển hóa (MAFLD): bệnh hệ thống ngoài gan

  2023cites this paper
• Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms

  2023cites this paper
• Aerobic exercise and vitamin E improve high-fat diet-induced NAFLD in rats by regulating the AMPK pathway and oxidative stress

  2023cites this paper
• Vitamin E induces liver iron depletion and alters iron regulation in mice.

  2023cites this paper
• Nutritional and Lifestyle Therapy for NAFLD in People with HIV

  2023cites this paper
• PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.

  2023cites this paper
• Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes

  2023cites this paper
• Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology.

  2023cites this paper
• AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

  2023cites this paper
• Diabetes and cirrhosis: Current concepts on diagnosis and management

  2023cites this paper
• Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies.

  2022cites this paper
• Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis

  2022cites this paper
• The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

  2022cites this paper
• Spontaneous regression of cirrhosis: a paradigm shift in our understanding of the natural history of non-alcoholic steatohepatitis (NASH).

  2022cites this paper
• Oxidative Stress in Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• Platelet-neutrophil hybrid membrane-coated gelatin nanoparticles for enhanced targeting ability and intelligent release in the treatment of non-alcoholic steatohepatitis.

  2022cites this paper
• Antifibrogenic and apoptotic effects of Ocoxin in cultured rat hepatic stellate cells

  2022cites this paper
• Combination Effects of Metformin and a Mixture of Lemon Balm and Dandelion on High-Fat Diet-Induced Metabolic Alterations in Mice

  2022cites this paper
• Fat Grafts Augmented With Vitamin E Improve Volume Retention and Radiation-Induced Fibrosis.

  2022cites this paper
• SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).

  2022cites this paper
• Letter to the editor: Spontaneous regression of cirrhosis: A paradigm shift in our understanding of the natural history of NASH

  2022cites this paper
• Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD

  2022cites this paper
• Current treatment of non‐alcoholic fatty liver disease

  2022cites this paper
• An overview of ferroptosis in non-alcoholic fatty liver disease.

  2022cites this paper
• The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies

  2022cites this paper
• Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

  2022cites this paper
• Management of NAFLD in primary care settings

  2022cites this paper
• Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

  2022cites this paper
• Approach to the Patient with Nonalcoholic Fatty Liver Disease.

  2022cites this paper
• Bariatric endoscopic-surgical therapies for NAFLD. Should they be considered viable options among current treatments?

  2022cites this paper
• Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences

  2022cites this paper
• Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).

  2022cites this paper
• Preparing for the NASH Epidemic: A Call to Action

  2021cites this paper
• Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).

  2021cites this paper